Ovarian Cancer

Travel Insurance for Ovarian Cancer Patients

Ovarian cancer is diagnosed in approximately 380 women each year. It is often detected at a later stage than some other cancers, which means many women considering travel are doing so while managing ongoing treatment or monitoring rather than in clear remission.

Coverability Assessment

Travel insurance for ovarian cancer is assessed on a case-by-case basis by all providers. The key variables are:

• Stage at diagnosis and current disease status
• Type and current status of treatment (surgery, platinum-based chemotherapy, PARP inhibitors, bevacizumab)
• CA-125 levels and trend — a rising CA-125 may indicate recurrence and will affect assessment
• Time since last treatment
• Presence of complications such as ascites, pleural effusion, or bowel involvement

Women who have completed first-line treatment (debulking surgery + chemotherapy) and are in remission with a stable CA-125 have the best prospects for coverage with an additional premium. Those on maintenance therapy (e.g. olaparib/niraparib PARP inhibitors) are generally also assessable.

Chemotherapy Cycles and Travel Windows

If you are currently on platinum-based chemotherapy (carboplatin, cisplatin), paclitaxel, or combination regimens, your immune function fluctuates significantly through the cycle. The "nadir" — the lowest point of white blood cell count, typically 7–14 days after each infusion — is the highest-risk period for infection and travel complications.

The safest window for travel during active chemotherapy is generally Days 7–14 after your nadir recovers, in the second half of each cycle. This must be confirmed with your oncologist before booking anything.

CA-125 Monitoring

CA-125 is the primary tumour marker used to monitor ovarian cancer. Regular testing (typically every 3 months in remission, more frequently during active treatment) is important. If your overseas trip extends beyond your next scheduled test, discuss with your oncologist whether:

• Testing can be safely delayed
• Testing can be arranged at an overseas laboratory
• Your CA-125 trend is stable enough to allow extended travel

PARP Inhibitors and Maintenance Therapy

PARP inhibitors (olaparib/Lynparza, niraparib/Zejula, rucaparib/Rubraca) are taken as daily oral tablets. They are generally well-tolerated for travel purposes. Carry in your original pharmacy packaging. Be aware that PARP inhibitors can cause fatigue, nausea, and occasional haematological side effects — relevant for high-activity itineraries.

Destination Priorities

Choose destinations with gynaecological oncology capability. If you develop an ovarian cancer-related complication overseas, you need access to a team that understands ovarian cancer management:

• Australia: Excellent, easy air transfer home
• Singapore: World-class oncology facilities
• United Kingdom: NHS has good oncology capability
• USA: Excellent facilities but very high cost — unlimited medical cover essential
• Pacific Islands: Limited — medical evacuation cover critical
• Rural Southeast Asia: Avoid for high-risk periods

Key Takeaway

Ovarian cancer does not stop you from travelling. Between treatment cycles with medical clearance, or in remission with stable CA-125, most insurers will assess your case. Declare fully, carry your documentation, and choose destinations wisely.